Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-targeted CAR-T cells for relapsed/refractory multiple myeloma
NCT04670055Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCMA targeted CAR T-cells in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoint: Dose-limiting toxicity at 28 days. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
BCMA targeted CAR T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04670055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670055.